查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1422820

2024-2032 年男性性腺功能减退症市场报告（依治疗类型、药物传递、应用和地区）

Male Hypogonadism Market Report by Therapy Type, Drug Delivery, Application, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

2023年，全球男性性腺功能减退症市场规模达到37亿美元。展望未来， IMARC Group预计到2032年市场规模将达到56亿美元，2024-2032年复合年增长率（CAGR）为4.54%。男性睪固酮缺乏症盛行率的大幅上升、患者群体对男性性腺功能减退症治疗选择的认识不断提高以及健康意识的增强是推动市场的一些关键因素。

男性性腺功能减退症是一种睪丸无法产生足够睪固酮的疾病，导致肌肉生长不足、毛髮生长受损、乳房发育受损、声音低沉。这种疾病的特征是男性缺乏睪固酮或精子产生。它是由与睪丸（原发性性腺功能减退症）或下丘脑-脑下垂体轴（继发性性腺功能减退症）相关的疾病引起的。性腺机能减退症患者可能会遭受各种器官功能障碍以及生活品质下降，因为它源自于影响下视丘和脑下垂体的睪丸问题或疾病。男性性腺功能减退症可能是遗传性的，也可能是后天性的，由荷尔蒙失衡、药物或老化引起。几种先天性酵素异常会导致全身不同程度的雄性激素抵抗。性腺功能减退症最常见于 60 岁以上的男性，其症状和适应症也相应不同。

男性性腺功能减退症市场趋势：

全球市场的主要动力是男性睪固酮缺乏症盛行率大幅上升以及不孕率上升。这可归因于慢性生活方式障碍（包括肥胖和糖尿病）的发生率不断增加。与此一致的是，更容易患有男性性腺功能减退症的老年人口的不断扩大也为市场提供了动力。此外，患者群体对男性性腺功能减退症治疗选择的认识不断提高，也是一个重要的生长诱导因素。多个国家的政府机构正在提高人们对性腺功能减退症治疗方法的认识，包括睪固酮替代疗法（TST）。然而，与外部睪固酮激素注射相关的严重不良反应是男性性腺功能减退症市场的一个重要的成长限制因素。相反，临床试验数量的增加和新治疗方案的出现预计将在预测期内创造新的男性性腺功能减退症市场成长机会。除此之外，全球医疗基础设施发展的持续技术进步正在为市场创造积极的前景。促进市场发展的其他一些因素包括快速城市化、日益增强的健康意识、高额医疗支出以及广泛的研发（R&D）活动。

本报告回答的关键问题：

  • 迄今为止，全球男性性腺功能减退症市场表现如何，未来几年将如何表现？
  • 全球男性性腺功能减退症市场的驱动因素、限制因素和机会是什么？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的男性性腺功能减退症市场？
  • 根据治疗类型的市场划分是怎样的？
  • 基于药物输送的市场区隔是什么？
  • 基于应用程式的市场区隔是什么？
  • 全球男性性腺功能减退症市场的竞争结构如何？
  • 全球男性性腺功能减退症市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球男性性腺功能减退症市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依治疗类型

  • 睾酮替代疗法
    • 市场走向
    • 市场预测
  • 促性腺激素释放激素治疗
    • 市场走向
    • 市场预测

第 7 章：市场细分：依药物输送

  • 外用凝胶
    • 市场走向
    • 市场预测
  • 注射剂
    • 市场走向
    • 市场预测
  • 透皮贴剂
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：按应用

  • 卡尔曼症候群
    • 市场走向
    • 市场预测
  • 克氏综合症
    • 市场走向
    • 市场预测
  • 脑下垂体疾病
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc
    • Endo International Plc
    • Ferring Holding SA
    • Grunenthal GmbH
    • Lilly USA, LLC (Eli Lilly and Company)
    • Pfizer Inc
    • Sun Pharmaceutical Industries Limited
    • Teva Pharmaceutical Industries Ltd
Product Code: SR112024A7206

Abstract

The global male hypogonadism market size reached US$ 3.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.6 Billion by 2032, exhibiting a growth rate (CAGR) of 4.54% during 2024-2032. A considerable rise in the prevalence of testosterone deficiency in males, the rising awareness of male hypogonadism treatment choices among the patient population, and increasing health consciousness represent some of the key factors driving the market.

Male hypogonadism is a medical condition in which the testes fail to produce enough testosterone, leading to a lack of muscle growth, impaired hair growth, breast development, as well as a lack of deepening of the voice. The medical condition is characterized by a lack of testosterone or spermatozoa production in men. It is caused owing to the disorder related to the testes (primary hypogonadism) or the hypothalamic-pituitary axis (secondary hypogonadism). An individual with hypogonadism may suffer from a variety of organ dysfunctions as well as a reduction in quality of life since it originates from a testicular problem or disorder that affects the hypothalamus and pituitary gland. Hypogonadism in men can be genetic or acquired, caused by hormonal imbalances, medications or aging. Several congenital enzyme abnormalities are responsible for causing different degrees of androgen resistance throughout the body. Hypogonadism is most common in men over the age of 60, and the symptoms and indications of the deficiency vary accordingly.

Male Hypogonadism Market Trends:

The global market is primarily driven by a considerable rise in the prevalence of testosterone deficiency in males, along with the growing infertility rates. This can be attributed to the increasing incidences of chronic lifestyle disorders, including obesity and diabetes. In line with this, the expanding geriatric population that is more susceptible to developing male hypogonadism is also providing an impetus to the market. Moreover, the rising awareness of male hypogonadism treatment choices among the patient population is also acting as a significant growth-inducing factor. Government bodies across several countries are promoting awareness of hypogonadism treatment methods, including testosterone replacement therapy (TST). However, severe adverse reactions associated with external testosterone hormone injections are acting as a significant growth-restraining factor for the male hypogonadism market. Conversely, the increasing number of clinical trials and the emergence of new treatment options are expected to create new male hypogonadism market opportunities for growth during the forecast period. Apart from this, continual technological advancements in the development of medical infrastructure on the global level are creating a positive outlook for the market. Some of the other factors contributing to the market include rapid urbanization, increasing health consciousness, high medical expenditure and extensive research and development (R&D) activities.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global male hypogonadism market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on therapy type, drug delivery and application.

Therapy Type Insights

Testosterone Replacement Therapy

Gonadotropin-Releasing Hormones Therapy

The report has provided a detailed breakup and analysis of the male hypogonadism market based on the therapy type. This includes testosterone replacement therapy and gonadotropin-releasing hormones therapy. According to the report, testosterone replacement therapy represented the largest segment.

Drug Delivery Insights

Topical Gels

Injectables

Transdermal Patches

Others

The report has provided a detailed breakup and analysis of the male hypogonadism market based on the drug delivery. This includes topical gels, injectables, transdermal patches, and others. According to the report, topical gels represented the largest segment.

Application Insights

Kallmann Syndrome

Klinefelters Syndrome

Pituitary Disorders

Others

A detailed breakup and analysis of the male hypogonadism market based on the application has also been provided in the report. This includes Kallmann Syndrome, Klinefelters Syndrome, pituitary disorders, and others.

Regional Insights

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for male hypogonadism. Some of the factors driving the North America male hypogonadism market include the growing geriatric population, rising prevalence of sedentary lifestyle and related medical conditions, increasing number of clinical trials, the emergence of new treatment options, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global male hypogonadism market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc, Endo International Plc, Ferring Holding S.A, Grunenthal GmbH, Lilly USA, LLC (Eli Lilly and Company), Pfizer Inc, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd, etc.

Key Questions Answered in This Report:

  • How has the global male hypogonadism market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global male hypogonadism market?
  • What are the key regional markets?
  • Which countries represent the most attractive male hypogonadism markets?
  • What is the breakup of the market based on the therapy type?
  • What is the breakup of the market based on the drug delivery?
  • What is the breakup of the market based on the application?
  • What is the competitive structure of the global male hypogonadism market?
  • Who are the key players/companies in the global male hypogonadism market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Male Hypogonadism Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy Type

  • 6.1 Testosterone Replacement Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Gonadotropin-Releasing Hormones Therapy
    • 6.2.1 Market Trends
    • 6.2.3 Market Forecast

7 Market Breakup by Drug Delivery

  • 7.1 Topical Gels
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectables
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Transdermal Patches
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Kallmann Syndrome
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Klinefelters Syndrome
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Pituitary Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Endo International Plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Ferring Holding S.A
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Grunenthal GmbH
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 SWOT Analysis
    • 14.3.5 Lilly USA, LLC (Eli Lilly and Company)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Pfizer Inc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Sun Pharmaceutical Industries Limited
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Teva Pharmaceutical Industries Ltd
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio

List of Figures

  • Figure 1: Global: Male Hypogonadism Market: Major Drivers and Challenges
  • Figure 2: Global: Male Hypogonadism Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Male Hypogonadism Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Male Hypogonadism Market: Breakup by Therapy Type (in %), 2023
  • Figure 5: Global: Male Hypogonadism Market: Breakup by Drug Delivery (in %), 2023
  • Figure 6: Global: Male Hypogonadism Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Male Hypogonadism Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Male Hypogonadism (Testosterone Replacement Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Male Hypogonadism (Testosterone Replacement Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Male Hypogonadism (Gonadotropin-Releasing Hormones Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Male Hypogonadism (Gonadotropin-Releasing Hormones Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Male Hypogonadism (Topical Gels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Male Hypogonadism (Topical Gels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Male Hypogonadism (Injectables) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Male Hypogonadism (Injectables) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Male Hypogonadism (Transdermal Patches) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Male Hypogonadism (Transdermal Patches) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Male Hypogonadism (Other Drug Deliveries) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Male Hypogonadism (Other Drug Deliveries) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Male Hypogonadism (Kallmann Syndrome) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Male Hypogonadism (Kallmann Syndrome) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Male Hypogonadism (Klinefelters Syndrome) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Male Hypogonadism (Klinefelters Syndrome) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Male Hypogonadism (Pituitary Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Male Hypogonadism (Pituitary Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Male Hypogonadism (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Male Hypogonadism (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Male Hypogonadism Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Male Hypogonadism Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Male Hypogonadism Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Male Hypogonadism Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Male Hypogonadism Industry: Value Chain Analysis
  • Figure 79: Global: Male Hypogonadism Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Male Hypogonadism Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Male Hypogonadism Market Forecast: Breakup by Therapy Type (in Million US$), 2024-2032
  • Table 3: Global: Male Hypogonadism Market Forecast: Breakup by Drug Delivery (in Million US$), 2024-2032
  • Table 4: Global: Male Hypogonadism Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Male Hypogonadism Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Male Hypogonadism Market: Competitive Structure
  • Table 7: Global: Male Hypogonadism Market: Key Players